Responsive Playbooks and the CHE Inflection
This report analyzes Chemed Corp (NYSE: CHE) with a near-term neutral sentiment and mid/long-term strength, identifying a mid-channel oscillation pattern. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss levels. The analysis highlights an exceptional 32.2:1 risk-reward setup, targeting a 9.3% gain against 0.3% risk.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 13 November By Investing.com
This article reports on a Form 4 filing for Chemed Corp, detailing a transaction made by Spencer S. Lee, an executive vice president, on November 13th. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The article indicates this is an insider trading report.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 13 November
This article reports on a Form 4 filing for Chemed Corp, detailing an insider transaction by Spencer S. Lee, an executive vice president, on November 13. Form 4 filings are regulatory documents that disclose changes in ownership of company stock by insiders. The article indicates that this filing is related to Chemed Corp, which trades under the symbol CHE.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 11 November
This article reports on a Form 4 filing for Chemed Corp, detailing an insider transaction by Spencer S. Lee, an executive vice president. The filing pertains to activity on November 11. The article includes the company's stock symbol CHE.
Chemed Corp executive vice president sells $547,610 in stock
Spencer S. Lee, Executive Vice President of Chemed Corp (NYSE:CHE), sold 1,000 shares of the company's stock for a total of $547,610 on November 11, 2026. Following this transaction, Mr. Lee directly holds 12,931 shares. The sale occurred while Chemed's stock was trading near its 52-week high, having risen 29% year-to-date, though InvestingPro analysis suggests it may still be undervalued.
Chemed (NYSE:CHE) EVP Sells 1,000 Shares of Stock
Chemed Corporation's EVP, Spencer Lee, sold 1,000 shares of the company's stock for $547,610, reducing his direct ownership by 7.18%. This transaction follows Chemed reporting better-than-expected quarterly earnings and revenue, alongside a declared quarterly dividend of $0.70 per share. The company currently holds an average analyst rating of "Hold" with a target price of $603.
Can Chemed (CHE) Justify Its Valuation On Higher Earnings?
Chemed (CHE) has reported higher net income and earnings per share for Q3 and the first nine months of 2026, leading to a share price of US$528.05 and a year-to-date return of 24.6%. Analysts view Chemed as 21.8% undervalued with a fair value of $675, citing growth drivers in both its VITAS hospice care and Roto-Rooter plumbing services, though potential risks exist in Medicare Cap setbacks and rising digital lead costs. Investors are encouraged to assess the company's valuation against both its growth prospects and these identified risks.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 2 November
This article reports on a Form 4 filing for Chemed Corp, detailing insider transactions by Spencer S. Lee, an executive vice president, on November 2nd. The filing provides transparency into executive stock ownership and trading activities within the company, which is often monitored by investors for insights into management's confidence in the company's future.
Chemed executive vice president Lee sells $494,196 in stock By Investing.com
Spencer S. Lee, an executive vice president at Chemed Corp., sold 920 shares of the company's stock for a total of $494,196 on November 2, 2026. This transaction occurred while the stock was trading near its 52-week high, and Lee now directly holds 13,931 shares. Chemed recently reported strong third-quarter 2026 earnings, exceeding Wall Street expectations, and has consistently raised its dividend for 17 consecutive years.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 2 November
This article reports on a Form 4 filing for Chemed Corp, detailing an insider transaction by Spencer S. Lee, who serves as an executive vice president. The filing pertains to activity on November 2nd. The article provides the title of the Form 4 and notes the company's stock symbol CHE.
Chemed Corporation $CHE Holdings Lowered by Alps Advisors Inc.
Alps Advisors Inc. significantly reduced its holdings in Chemed Corporation by 24% in the third quarter, selling 9,809 shares and ending with 30,986 shares valued at $15.65 million. Despite insider selling by executives, Chemed reported strong quarterly results, beating EPS consensus and increasing revenue by 10.6% year over year. The stock currently holds an average analyst rating of "Hold" with a target price of $603.00.
Form 144 Chemed Corporation For: 7 November By Investing.com
This article reports on a Form 144 filing by Chemed Corporation for November 7th. Form 144 is a notice of the intent to sell restricted stock. The article is a brief announcement from Investing.com.
Chemed Corporation (CHE) Declares Quarterly Dividend of $0.70 Per Share
Chemed Corporation (NYSE: CHE) announced a quarterly dividend of $0.70 per share, maintaining its previous payout. The company is considered modestly undervalued by GuruFocus' GF Value™ and has a strong GF Score™ of 86/100, reflecting solid financial health and profitability, despite recent net insider selling.
Chemed Corporation Declares Quarterly Dividend of 70 Cents
Chemed Corporation announced its Board of Directors has declared a quarterly cash dividend of 70-cents per share, payable on December 4, 2026, to shareholders of record as of November 16, 2026. This marks the 222nd consecutive quarterly dividend for the company, which operates VITAS Healthcare and Roto-Rooter.
Chemed Corp president and CEO Kevin McNamara sells $1.08 million in stock
Kevin J. McNamara, President and CEO of Chemed Corp, sold 2,000 shares of company stock worth $1.08 million on November 3, 2026. This sale occurred while the stock was trading near its 52-week high, following a significant 26% gain in the past six months, although InvestingPro analysis suggests the company may still be undervalued. After the transaction, McNamara directly holds 82,220 shares.
Form 4 Chemed Corp: Kevin J. Mcnamara (Director, president and CEO) For: 3 November By Investing.com
This article reports on a Form 4 filing for Chemed Corp, detailing a transaction by Kevin J. Mcnamara, who holds positions as Director, President, and CEO. The filing pertains to activity on November 3rd and is published by Investing.com, also noting a 2.71% decrease in CHE's stock.
At an average $537.90 a share, Chemed (CHE) CEO sells 2,000 shares.
Chemed Corp (CHE) President and CEO Kevin J. McNamara sold 2,000 shares of capital stock on November 3, 2026, at a weighted-average price of $537.90 per share. The transactions ranged from $532.34 to $546.52, reducing his direct holdings to 82,220 shares after the sale. The reported share count was also corrected for an administrative error from a previous filing.
Form 4 Chemed Corp: Kevin J. Mcnamara (Director, president and CEO) For: 3 November
This article reports on a Form 4 filing for Chemed Corp (CHE), indicating an insider transaction by Kevin J. Mcnamara, who holds positions as Director, President, and CEO. The filing is related to activity on November 3rd, and the article was published on November 6, 2026, at 01:20 a.m.
Chemed (CHE) executive Lee sold 920 Capital Stock for $494K at $537.17
Spencer S. Lee, Executive Vice President at Chemed Corp (CHE), sold 920 shares of Capital Stock for $494,196 at a weighted average price of $537.17 per share on November 2, 2026. This transaction reduced his direct holdings by 6% to 13,931 units. The sale was an open-market transaction, and the filing did not mention a Rule 10b5-1 trading plan.
After selling 920 shares, Chemed (CHE) EVP Spencer S. Lee holds 13,931 shares directly.
Spencer S. Lee, Executive Vice President of Chemed Corp (CHE), sold 920 shares of the company's Capital Stock on November 2, 2026, at a weighted average price of $537.17 per share. Following this transaction, Lee's direct holdings in Chemed Corp amount to 13,931 shares. No Rule 10b5-1 plan was reported for the sale.
Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
Chemed Corporation announced it will present at the UBS 2026 Global Healthcare Conference on Monday, November 9, 2026, at approximately 8:45 a.m. (ET). The presentation will be webcast live on the company's website. Chemed operates two subsidiaries: VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing and drain cleaning service.
Chemed Corporation $CHE Stock Sold by ProShare Advisors LLC
ProShare Advisors LLC significantly reduced its stake in Chemed Corporation by 23.3% in the third quarter, selling 16,516 shares and retaining 54,245 shares valued at approximately $27.4 million. Despite institutional ownership by 95.85% of the stock, analyst sentiment is mixed but improving, with a consensus "Hold" rating and an average target price of $603. Chemed reported strong quarterly earnings, beating estimates, with revenue up 10.6% year-over-year, and increased its quarterly dividend to $0.70 per share.
Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
Chemed Corporation announced it will present at the UBS 2026 Global Healthcare Conference on Monday, November 9, 2026, at approximately 8:45 a.m. (ET). The presentation will be webcast live from the PGA National Resort in Palm Beach Gardens, Florida, and accessible via the company's website. Chemed operates two wholly owned subsidiaries: VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing and drain cleaning service.
Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
Chemed Corporation announced it will present at the UBS 2026 Global Healthcare Conference on Monday, November 9, 2026, at approximately 8:45 a.m. (ET). The presentation will be webcast live from the PGA National Resort in Palm Beach Gardens, Florida, and accessible via the company's investor relations website, with a replay available for 90 days. Chemed operates two subsidiaries, VITAS Healthcare and Roto-Rooter.
Chemed Corp Stock 12‑Month Price Target Raised to $597.6, Implies 17% Upside
Chemed Corp's average price target has been increased from $571.6 to $597.6 by 5 analysts, with forecasts ranging from $548 to $650 per share. This new target suggests a potential upside of approximately 17% from the Oct. 27 closing price. The consensus rating for the stock has shifted to "Buy" among 6 covering analysts.
Chemed: Q3 Earnings Snapshot
Chemed Corp. (CHE) reported a third-quarter profit of $71.6 million, or $5.45 per share. Adjusted earnings for the Cincinnati-based company, which operates Roto-Rooter and Vitas Healthcare, were $6.75 per share, with revenue reaching $690.9 million.
Chemed Corp stock hits 52-week high at 558.32 USD
Chemed Corp's stock reached a 52-week high of $558.32, reflecting a 15.99% increase over the past year and underscoring strong investor confidence. The company has a market capitalization of $7.2 billion and has consistently raised its dividend for 17 consecutive years. Recent news includes exceeding Wall Street expectations in Q2 earnings and upgrades from Jefferies and UBS with positive price targets.
Chemed Corp stock hits 52-week high at 558.32 USD By Investing.com
Chemed Corp's stock has reached a 52-week high of $558.32, reflecting a 15.99% increase over the past year and strong investor confidence. The stock is considered undervalued by InvestingPro analysis, and the company has consistently raised its dividend for 17 years. Recent positive financial results and upgraded analyst ratings from Jefferies and UBS further support a positive outlook for Chemed's continued growth.
Chemed Q3 2026 Earnings Call Transcript
Chemed Corporation reported robust financial results for Q3 2026, with total revenue increasing by 10.6% and adjusted diluted EPS rising by 28.1% year-over-year. The VITAS Healthcare segment saw a 12.2% revenue increase due to ADC growth and cost control, while Roto-Rooter's revenue grew 7.5%, supported by acquisitions and strong same-store sales despite higher marketing costs. The company completed $66 million in share repurchases and remains confident in exceeding its full-year 2026 adjusted EPS guidance, with a continued focus on strategic acquisitions to drive long-term growth.
CHE: VITAS drove Q3 growth as Roto-Rooter margins weakened; FY adjusted EPS is tracking at or above guidance high end
Chemed Corp (CHE) reported increased Q3 revenue and adjusted EPS, primarily driven by growth and margin expansion in its VITAS segment. While Roto-Rooter's revenue grew, its adjusted EBITDA declined. The company anticipates its FY 2026 adjusted EPS to be at or slightly above the high end of its guidance.
Chemed Q3 Revenue Rises 10.6%; Adjusted Diluted EPS Reaches $6.75
Chemed reported a significant increase in its third-quarter 2026 revenue, rising 10.6% year over year to $690.9 million, with adjusted diluted EPS reaching $6.75. The company's VITAS segment showed strong growth, offsetting a slight decrease in Roto-Rooter's adjusted EBITDA. Key highlights include VITAS's average daily census growth and Roto-Rooter's reacquisition of California franchise territories.
Chemed earnings on deck: Hospice growth faces Roto-Rooter test
Chemed Corp is set to report third-quarter earnings, with investors focused on whether its VITAS Healthcare hospice unit can continue to offset challenges faced by its Roto-Rooter plumbing business. Analysts project earnings of $6.44 per share on $685.04 million in revenue, anticipating growth driven by hospice demand and strategic acquisitions. The company's dual-business model faces a test, with strong hospice performance potentially bolstering shares despite Roto-Rooter's recovery timeline.
Form 4 Chemed Corp: Thomas C. Hutton (Director, vice president) For: 28 September By Investing.com
This article reports on a Form 4 filing for Chemed Corp, detailing a transaction by Thomas C. Hutton, who serves as both a Director and Vice President, for September 28. The brief update is sourced from Investing.com and provides a direct link to view all associated comments.
Form 4 Chemed Corp: Kevin J. Mcnamara (Director, president and CEO) For: 28 September By Investing.com
This article reports on a Form 4 filing for Chemed Corp, detailing a transaction by Kevin J. Mcnamara, who serves as a Director, President, and CEO. The filing pertains to activities that occurred on September 28. The brief notice highlights the company and the individual involved in the insider transaction.
Form 4 Chemed Corp: Kevin J. Mcnamara (Director, president and CEO) For: 28 September
This article reports on a Form 4 filing for Chemed Corp, detailing an insider transaction by Kevin J. Mcnamara, who holds the positions of Director, President, and CEO. The transaction date specified in the filing is September 28. The article does not provide further details on the nature of the transaction.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 30 September
This article reports on a Form 4 filing for Chemed Corp, detailing an insider transaction by Spencer S. Lee, an executive vice president. The filing pertains to activities that occurred on September 30. The article itself is very brief, simply stating the fact of the filing.
Form 4 Chemed Corp: Spencer S. Lee (executive vice president) For: 20 October
This article reports on a Form 4 filing for Chemed Corp, detailing insider transactions by Spencer S. Lee, an executive vice president. The filing specifically covers activity on October 20th. It provides concise information without further details on the nature of the transactions.
Form 4 Chemed Corp: Michael D. Witzeman (VP & Chief Financial Officer) For: 20 October
This article reports on a Form 4 filing for Chemed Corp, indicating a transaction involving Michael D. Witzeman, the VP & Chief Financial Officer, on October 20. The filing pertains to Chemed Corp, trading under the ticker CHE. The content emphasizes the importance of insider trading information for investors.
Form 4 Chemed Corp: Brian C. Judkins (VP and Chief Legal Officer) For: 20 October By Investing.com
This article reports on a Form 4 filing for Chemed Corp, detailing an insider transaction by Brian C. Judkins, the VP and Chief Legal Officer. The filing pertains to activity on October 20th. The article is from Investing.com and was published on October 22, 2026.
Form 4 Chemed Corp: Joel L. Wherley (CEO - Vitas Healthcare) For: 20 October
This article reports on a Form 4 filing for Chemed Corp concerning Joel L. Wherley, CEO of Vitas Healthcare, for transactions on October 20. It includes the stock symbol CHE and was published by Investing.com.
A 12,686-share option award at Chemed (CHE) goes to Vitas Healthcare CEO Joel L. Wherley.
Chemed Corp. (CHE) has granted Joel L. Wherley, CEO of Vitas Healthcare, a stock-option award covering 12,686 shares. These options have an exercise price of $512.64 per share and will vest in three equal annual installments beginning October 20, 2027. This transaction, filed on October 22, 2026, results in Wherley's reported option position increasing to 42,906 underlying shares.
Thomas C. Hutton Acquires 3,964 Stock Options in Chemed Corp at $512.64 Exercise Price
Thomas C. Hutton, a director and vice president at Chemed Corp (NYSE:CHE), acquired 3,964 stock options on October 20, 2026, with an exercise price of $512.64 per share. These options, which expire on October 20, 2031, will vest in three equal annual installments beginning October 20, 2027. Following this transaction, Hutton's direct holdings of derivative securities total 26,053, exercisable into Chemed Capital Stock.
Form 4 Chemed Corp: Kevin J. Mcnamara (Director, president and CEO) For: 20 October
This article reports on a Form 4 filing for Chemed Corp (CHE), detailing an insider transaction by Kevin J. Mcnamara, who holds positions as Director, President, and CEO. The filing pertains to activity on October 20. The article itself provides minimal detail beyond the headline, focusing on the announcement of the SEC filing.
Form 4 CHEMED CORP For: Oct 20 Filed by: MCNAMARA KEVIN J
Kevin J. McNamara, President and CEO of CHEMED CORP, filed a Form 4 detailing the acquisition of 36,693 derivative securities (stock options) with a price of $512.64 on October 20, 2026. These options will vest in three equal annual installments starting October 20, 2027, adding to his beneficial ownership of 300,851 shares. The filing indicates his role as both a Director and Officer of the company.
Chemed (CHE) Set to Release Quarterly Earnings on Tuesday
Chemed (CHE) is scheduled to release its Q3 2026 earnings after market close on Tuesday, October 27th, with analysts forecasting earnings of $6.39 per share and $685.04 million in revenue. The company previously surpassed Q2 expectations with $6.06 EPS and $673.25 million in revenue and recently increased its quarterly dividend to $0.70 per share. Despite mixed analyst sentiment, with an average "Hold" rating, Chemed has seen insider stock sales and some analyst upgrades.
49,765 Chemed Corporation $CHE Shares Sold by Fort Washington Investment Advisors Inc. OH
Fort Washington Investment Advisors Inc. OH significantly reduced its stake in Chemed Corporation (NYSE:CHE) by selling 49,765 shares, leaving them with 1,248 shares valued at $630,000. Despite this, Chemed reported strong quarterly earnings, beating estimates with $6.06 EPS and an 8.8% revenue increase, and also raised its quarterly dividend to $0.70 per share. Analysts generally hold a "Hold" rating on the stock, with an average target price of $554.60, though UBS initiated coverage with a "Buy" rating and a $650 target.
Roto-Rooter Services Company Expands California Service Coverage to Reach 11M+ More Residents
Roto-Rooter Services Company, a subsidiary of Chemed Corporation, has acquired the largest independent Roto-Rooter franchise in California, significantly expanding its service coverage to approximately 11 million more residents. This acquisition, along with a smaller one in Marin County, extends plumbing, drain, sewer, and water cleanup services to numerous new markets, bringing Roto-Rooter's company-owned California coverage close to completion and its national reach to about 75% of the U.S. population. The expansion aims to provide more consistent and responsive service to both residential and national commercial customers across a wider array of communities.
Chemed Corp (CHE) Stock forecasts
Argus has issued a report on Chemed Corp (CHE), lowering its target price for the stock to $526.00. The report notes that Chemed Corp focuses on purchasing, operating, and divesting subsidiaries to maximize shareholder value. The current price of CHE is $512.38.
Chemed Corporation (NYSE:CHE) Stock Now Rated "Hold" by Sell-Side Analysts
Chemed Corporation (NYSE:CHE) has received an average "Hold" rating from sell-side analysts, with five out of seven firms recommending a neutral stance and two a buy. The company recently reported quarterly earnings of $6.06 per share, surpassing estimates, and saw an 8.8% year-over-year revenue increase. Despite an increase in its quarterly dividend, company insiders sold a significant number of shares, while institutional investors hold a substantial portion of the stock.
(CHE) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Chemed Corp (NYSE: CHE) based on AI-generated signals and institutional trading strategies. It highlights neutral near and mid-term readings but a strong long-term positive bias, with an exceptional risk-reward setup targeting a 10.1% gain. The analysis offers specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies across different time horizons.